Mirati Therapeutics stock (NASDAQ: MRTX) has risen a solid 20% in a month, outperforming the broader markets with the S&P500 down 6%.
Mirati Therapeutics stock (NASDAQ: MRTX) has risen a solid 20% in a month, outperforming the broader markets with the S&P500 down 6%.